Skip to main content
Erschienen in: Supportive Care in Cancer 2/2016

01.02.2016 | Original Article

Skeletal related events in patients with bone metastasis arising from non-small cell lung cancer

verfasst von: Gustavo Telles da Silva, Anke Bergmann, Luiz Claudio Santos Thuler

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The skeleton is one of the most common sites of metastasis in patients with non-small cell lung cancer (NSCLC). Metastasis increases the risk of skeletal-related events (SREs). The purpose of this study is to evaluate the incidence of SREs and the factors associated with the development of SREs in patients with bone metastases (BM) arising from NSCLC.

Methods

A cohort study was carried out involving 95 patients with BM associated with NSCLC who were enrolled between 2007 and 2011. Clinical and sociodemographic data were extracted from the physical and electronic records. The association between exposure variables and outcome (SREs) was assessed using crude odds ratio (OR). Survival analysis of patients with BM was conducted using the Kaplan-Meier method. A log-rank test was used to assess differences between the curves of those who did and did not experience SREs.

Results

Sixty-two out of 95 patients with BM (65.3 %) showed evidence of at least one SRE. Multiple analysis revealed that patients with a history of smoking (OR = 6.76; 95% CI = 1.3–33.0; p < 0.01), performance status ≥2 (OR = 3.38; 95% CI = 1.2–9.3; p < 0.01), and multiple BM (OR = 3.31; 95% CI = 1.1–9.9; p < 0.03) were at greater risk of SREs. Median survival time was 4.6 months (95% CI = 2.9–6.2) in patients who experienced SREs and 6.8 months (95% CI = 2.2–11.4) in patients who did not, a statistically significant difference (p = 0.03).

Conclusion

Patients with NSCLC are more likely to experience SREs if they have poor performance status, a history of smoking or multiple BM. Global survival was shorter in patients who suffer SREs.
Literatur
2.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 94:153PubMedCrossRef Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 94:153PubMedCrossRef
3.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30PubMedCrossRef Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30PubMedCrossRef
4.
Zurück zum Zitat Kohler BA, Wand E, McCarthy BJ et al (2011) Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103:714–736PubMedPubMedCentralCrossRef Kohler BA, Wand E, McCarthy BJ et al (2011) Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103:714–736PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Hirsh V (2009) Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer. Clin Lung Cancer 10(4):223–229PubMedCrossRef Hirsh V (2009) Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer. Clin Lung Cancer 10(4):223–229PubMedCrossRef
7.
Zurück zum Zitat Al Husaini H, Wheatley-Price P, Clemons M et al (2009) Prevention and management of bone metastases in lung cancer: a review. J Thorac Oncol 4:251–259PubMedCrossRef Al Husaini H, Wheatley-Price P, Clemons M et al (2009) Prevention and management of bone metastases in lung cancer: a review. J Thorac Oncol 4:251–259PubMedCrossRef
8.
Zurück zum Zitat Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176PubMedCrossRef Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176PubMedCrossRef
10.
11.
Zurück zum Zitat Tsuya A, Kurata T, Tamura K et al (2007) Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 57(2):229–232PubMedCrossRef Tsuya A, Kurata T, Tamura K et al (2007) Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 57(2):229–232PubMedCrossRef
12.
Zurück zum Zitat Hoefeler H, Duran I, Hechmati G et al (2014) Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective–prospective observational study—a cohort from 4 European countries. J Bone Oncol 3(2):40–48CrossRef Hoefeler H, Duran I, Hechmati G et al (2014) Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective–prospective observational study—a cohort from 4 European countries. J Bone Oncol 3(2):40–48CrossRef
13.
Zurück zum Zitat Mu Sun J, Ahn JS, Lee S et al (2011) Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer 71(1):89–93CrossRef Mu Sun J, Ahn JS, Lee S et al (2011) Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer 71(1):89–93CrossRef
14.
Zurück zum Zitat Decroisette C, Monnet I, Berard H et al (2011) Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study. J Thorac Oncol 6(3):573–582CrossRef Decroisette C, Monnet I, Berard H et al (2011) Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study. J Thorac Oncol 6(3):573–582CrossRef
15.
Zurück zum Zitat Oster G, Lamerato L, Glass AG et al (2013) Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer 21(12):3279–3286PubMedCrossRef Oster G, Lamerato L, Glass AG et al (2013) Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer 21(12):3279–3286PubMedCrossRef
16.
Zurück zum Zitat Bae HM, Lee SH, Kim TM et al (2012) Prognostic factors for non-small cell lung cancer with bone metastasis at the time diagnosis. Lung Cancer 77(3):572–577PubMedCrossRef Bae HM, Lee SH, Kim TM et al (2012) Prognostic factors for non-small cell lung cancer with bone metastasis at the time diagnosis. Lung Cancer 77(3):572–577PubMedCrossRef
17.
Zurück zum Zitat Sathiakumar N, Delzell E, Morrisey MA et al (2013) Mortality following bone metastasis and skeletal-related events among patients 65 years and above with lung cancer: a population-based analysis of U.S Medicare beneficiaries, 1999–2006. Lung Ind 30(1):20–26CrossRef Sathiakumar N, Delzell E, Morrisey MA et al (2013) Mortality following bone metastasis and skeletal-related events among patients 65 years and above with lung cancer: a population-based analysis of U.S Medicare beneficiaries, 1999–2006. Lung Ind 30(1):20–26CrossRef
18.
Zurück zum Zitat De Marini F, Eberhardt W, Harper PG et al (2009) Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol 4(10):1280–1288CrossRef De Marini F, Eberhardt W, Harper PG et al (2009) Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol 4(10):1280–1288CrossRef
19.
Zurück zum Zitat Wei J, Jun T, Pinghai Z et al (2011) Factors associated with the development of skeletal-related events in non-small cell lung cancer patients with bone metastases. Int J Radiat Oncol Biol Phys 81(2):S596CrossRef Wei J, Jun T, Pinghai Z et al (2011) Factors associated with the development of skeletal-related events in non-small cell lung cancer patients with bone metastases. Int J Radiat Oncol Biol Phys 81(2):S596CrossRef
20.
Zurück zum Zitat Katakami N, Kunikane H, Takeda K et al (2014) Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13. J Thorac Oncol 9(2):231–238PubMedPubMedCentralCrossRef Katakami N, Kunikane H, Takeda K et al (2014) Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13. J Thorac Oncol 9(2):231–238PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Nagata M, Kudoh S, Mitsuoka S et al (2013) Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations. Osaka City Med J 59(1):45–52PubMed Nagata M, Kudoh S, Mitsuoka S et al (2013) Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations. Osaka City Med J 59(1):45–52PubMed
22.
Zurück zum Zitat Cetin K, Christiansen CF, Jacobsen JB, NØrgarrd M, SØrensen HT (2014) Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study. Lung Cancer 86(2):247–254PubMedCrossRef Cetin K, Christiansen CF, Jacobsen JB, NØrgarrd M, SØrensen HT (2014) Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study. Lung Cancer 86(2):247–254PubMedCrossRef
23.
Zurück zum Zitat Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krazakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100:2613–2621PubMedCrossRef Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krazakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100:2613–2621PubMedCrossRef
24.
Zurück zum Zitat Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME (2013) Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev 39(1):97–104PubMedPubMedCentralCrossRef Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME (2013) Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev 39(1):97–104PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Lipton A, Fizazi K, Stopeck AT, Henry DA, Brown JE, Yardley DA, Richardson GA, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun SJ (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48(16):3082–3092PubMedCrossRef Lipton A, Fizazi K, Stopeck AT, Henry DA, Brown JE, Yardley DA, Richardson GA, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun SJ (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48(16):3082–3092PubMedCrossRef
26.
Zurück zum Zitat Ford J, Cummins E, Sharma P, Elders A, Stewart F, Johnston R, Royle P, Jones R, Mulatero C, Todd R, Mowatt G (2013) Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. Health Technol Assess 17(29):1–386PubMedCrossRef Ford J, Cummins E, Sharma P, Elders A, Stewart F, Johnston R, Royle P, Jones R, Mulatero C, Todd R, Mowatt G (2013) Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. Health Technol Assess 17(29):1–386PubMedCrossRef
27.
Zurück zum Zitat Wang Z, Qiao D, Lu Y, Curtis D, Wen X, Yao Y, Zhao H (2015) Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of sketetal-related events in cancer patients with bone metastasis. Oncologist 20(4):440–449PubMedCrossRef Wang Z, Qiao D, Lu Y, Curtis D, Wen X, Yao Y, Zhao H (2015) Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of sketetal-related events in cancer patients with bone metastasis. Oncologist 20(4):440–449PubMedCrossRef
28.
Zurück zum Zitat Lopez-Olivo MA, Shah NA, Pratt G et al (2012) Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Support Care Cancer 20(11):2985–2998PubMedPubMedCentralCrossRef Lopez-Olivo MA, Shah NA, Pratt G et al (2012) Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Support Care Cancer 20(11):2985–2998PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Henry D, Vadhan-Raj S, Hirsh V, Von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh H (2014) Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer 22(3):679–687PubMedCrossRef Henry D, Vadhan-Raj S, Hirsh V, Von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh H (2014) Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer 22(3):679–687PubMedCrossRef
30.
Zurück zum Zitat Sekine I, Nokihara H, Yamamoto N et al (2009) Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy. Lung Cancer 65(2):219–222PubMedCrossRef Sekine I, Nokihara H, Yamamoto N et al (2009) Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy. Lung Cancer 65(2):219–222PubMedCrossRef
31.
Zurück zum Zitat Ward KD, Klesges RC (2001) A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int 68:259–270PubMedCrossRef Ward KD, Klesges RC (2001) A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int 68:259–270PubMedCrossRef
32.
Zurück zum Zitat Williams AR, Weiss NS, Ure CL et al (1982) Effect of weight, smoking, and estrogen use on the risk of hip and forearm fractures in postmenopausal women. Obstet Gyncecol 60:695–699 Williams AR, Weiss NS, Ure CL et al (1982) Effect of weight, smoking, and estrogen use on the risk of hip and forearm fractures in postmenopausal women. Obstet Gyncecol 60:695–699
33.
Zurück zum Zitat Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, Richhariya A, Dodge T, Wolff GG, Balakumaran A, Edelsberg J (2014) Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer 22(4):1363–1373PubMedCrossRef Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, Richhariya A, Dodge T, Wolff GG, Balakumaran A, Edelsberg J (2014) Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer 22(4):1363–1373PubMedCrossRef
Metadaten
Titel
Skeletal related events in patients with bone metastasis arising from non-small cell lung cancer
verfasst von
Gustavo Telles da Silva
Anke Bergmann
Luiz Claudio Santos Thuler
Publikationsdatum
01.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 2/2016
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2835-1

Weitere Artikel der Ausgabe 2/2016

Supportive Care in Cancer 2/2016 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.